Recent Articles in Industry Insights

Deals and Financings 

• France's Sanofi will acquire Kadmon, a New York city pharma with a China JV and a newly approved graft-versus-host drug, in a $1.9 billion deal;
• Frontage Shanghai, a division of US-China CRO Frontage Holdings, acquired a 70% stake in Wuhan Heyan Biomedical Technology, a discovery CRO;
• Bio-Thera Solutions out-licensed US, EU and Canadian commercial rights for its Avastin biosimilar to Sandoz;
• Huadong Medicine entered a partnership with Insilico Medicine, a Hong Kong AI drug discovery company, to develop small-molecule oncology candidates; 

Covid-19 Pandemic 

• Brii Biosciences of Beijing committed an additional $100 million for global regulatory filings and commercialization of its SARS-CoV-2 combination therapy;
• Chengdu Clover Biopharma received a permit to manufacture its S-Trimer COVID-19 vaccine candidate at its Changxing facility;
• Sinovac Biotech said a third dose of its SARS-CoV-2 vaccine improved the protection of CoronaVac® by 60%, including protection from the Delta variant; 

Trials and Approvals 

• JW Therapeutics, a Shanghai CAR-T company, was approved to launch its anti-CD-19 CAR-T to treat large B-cell lymphoma in China. 

Stock Symbols: (NSDQ: KDMN) (SHA: 688177) (SHZ: 000963) (NSDQ: SVA) (HK: 2126)

In late May, Shanghai's municipal government announced a set of cash incentives for Shanghai companies that are developing new drugs, medical devices or signing contract manufacturing agreements. Shanghai will underwrite 40% of a novel drug's R&D expenses if the drug qualifies for China 1.1 status (candidates never approved anywhere). In addition, other new biologics will receive up to $1.5 million and chemical drugs $500,000, while new TCM therapies will be eligible for up to $4.5 million. The plan was originally described by Brian Yang of Pink Sheet (see article), who generously allowed ChinaBio™ Today to use the information. More details....

Share this with colleagues:

Just two months into 2021 and it already looks as though the momentum from 2020's record-setting levels of China life science activity continues into the new year. According to data compiled by ChinaBio® Group, most 2020 metrics for China life science doubled their 2019 results -- more partnerships, more investing, more drug development. Despite the disruptions of the COVID-19 pandemic, more companies found a way to forge new initiatives and advance their assets. The first few months of 2021 show the sector could equal or improve on its strong 2020 results. More details....